Outcome of the circular resolution dated January 05, 2026 for the reconstitution of the Audit and Nomination and Remuneration Committee of the Board.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pharmaids Pharmaceuticals has reconstituted two key board committees — the Audit Committee and the Nomination & Remuneration Committee — via a circular resolution passed on January 5, 2026, effective January 6, 2026. The Audit Committee will be chaired by Mr. Pattamadai Natarajasarma Vijay, with Mr. Methuku Nagesh, Dr. Yogananda Moolemath, and Mr. Venu Madhava Kaparthy as members. The Nomination & Remuneration Committee will be chaired by Mr. Methuku Nagesh, with Mr. Pattamadai Natarajasarma Vijay and Dr. Yogananda Moolemath as members. All members of both committees, except one whole-time director, are independent directors. The filing is a routine compliance disclosure under SEBI listing regulations.
This is a routine governance update with no change in top leadership or strategy. Shareholders are unlikely to see any material impact on the stock price from this announcement.